Labcorp stock (US50540R4092): Enhances Partnership with Epic for Lab Services

Labcorp, a leading provider of clinical laboratory and diagnostic services, recently enhanced its partnership with Epic, the major electronic health records platform. This move is designed to improve lab services integration and efficiency for healthcare providers. The announcement highlights Labcorp's focus on technological advancements in diagnostics, according to GuruFocus as of recent publication.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Labcorp: core business model

Labcorp operates as one of the largest independent clinical laboratories in the US, providing diagnostic testing services to healthcare providers, pharmaceutical companies, and patients. The company processes millions of tests annually through its network of primary labs and patient service centers. Labcorp also offers end-to-end drug development solutions, supporting clinical trials and companion diagnostics, which contribute significantly to its revenue stream.

This dual focus on routine clinical testing and specialized drug development positions Labcorp as a key player in the diagnostics sector. The company's scale allows it to handle high-volume testing, including for infectious diseases and cancer screenings, making it relevant for US investors tracking healthcare infrastructure.

Main revenue and product drivers for Labcorp

Labcorp's primary revenue comes from clinical diagnostics, accounting for the majority of its income through routine blood tests, pathology, and genetic screening. Drug development services, including central lab support for trials, represent a growing segment. In recent years, demand for COVID-19 testing boosted volumes, though the company has diversified into oncology and women's health testing.

Strategic partnerships like the one with Epic enhance data interoperability, potentially driving test volumes by simplifying ordering and result delivery for providers using Epic's widely adopted EHR system.

Industry trends and competitive position

The diagnostics industry is shifting toward precision medicine and digital integration, with Labcorp competing against Quest Diagnostics and smaller specialized labs. Labcorp holds about 20% of the independent lab market in the US, benefiting from its extensive network of over 2,000 patient service centers. Integration with EHR platforms like Epic addresses a key pain point in healthcare workflows.

Why Labcorp matters for US investors

Listed on the NYSE under ticker LH, Labcorp provides US investors exposure to the resilient diagnostics sector, which benefits from steady demand tied to an aging population and rising chronic disease prevalence. Its role in drug development links it to biotech innovation, a focal point for US markets.

Conclusion

The enhanced partnership with Epic underscores Labcorp's commitment to operational efficiency and technological integration in diagnostics. As healthcare digitizes, such collaborations could support long-term growth in test volumes and service adoption. Investors monitoring the sector will watch how this initiative impacts Labcorp's market position amid ongoing industry consolidation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.